NIBSC is part of a public–private consortium of 19 partners tasked with developing an alternative strategy for assessing the safety and quality of human and veterinary vaccines. Funded by the Innovative Medicines Initiative (IMI2), the VAC2VAC project will run for 5 years and brings together experts from the vaccine industry, academia and regulatory authorities. In addition to providing expert scientific and regulatory advice, NIBSC will lead on the development and evaluation of immunochemical methods for routine batch quality testing of vaccines including those that protect against diphtheria, tetanus and acellular pertussis.Read the press release in full.